Therapeutic approaches and drug-resistance in chronic lymphocytic leukaemia

Narjis Fatima, Kyle R. Crassini, Lauren Thurgood, Yandong Shen, Richard I. Christopherson, Bryone Kuss, Stephen P. Mulligan, Oliver Giles Best

Research output: Contribution to journalReview articlepeer-review

2 Downloads (Pure)

Abstract

The treatment of chronic lymphocytic leukaemia has been revolutionised in recent years, first by the introduction of chemoimmunotherapy regimens and subsequently by the development of drugs, including ibrutinib, idelalisib and venetoclax, that target components of the B-cell receptor signalling pathway or B-cell lymphoma 2 family of proteins. Despite high initial response rates in patients treated with chemoimmunotherapy or targeted agents, a significant proportion of patients relapse with progressive and refractory disease. In a subset of these patients, drug resistance has been associated with specific genetic lesions or activation of alternate pro-survival pathways. However, the mechanisms that confer drug resistance in the remainder of the patients with refractory disease have yet to be fully elucidated. In this review, we discuss our current understanding of the mechanics of drug resistance in chronic lymphocytic leukaemia and describe how this knowledge may aid in rationalising future treatment strategies to prevent the development of refractory or aggressive transformation of the disease.

Original languageEnglish
Pages (from-to)532-549
Number of pages18
JournalCancer Drug Resistance
Volume3
Issue number3
DOIs
Publication statusPublished - 2020

Keywords

  • Chronic lymphocytic leukaemia
  • Drug resistance
  • Targeted cancer therapy

Fingerprint

Dive into the research topics of 'Therapeutic approaches and drug-resistance in chronic lymphocytic leukaemia'. Together they form a unique fingerprint.

Cite this